IL109281A - Method of using xenon and / or krypton as contrast agents in magnetic resonance imaging - Google Patents
Method of using xenon and / or krypton as contrast agents in magnetic resonance imagingInfo
- Publication number
- IL109281A IL109281A IL10928194A IL10928194A IL109281A IL 109281 A IL109281 A IL 109281A IL 10928194 A IL10928194 A IL 10928194A IL 10928194 A IL10928194 A IL 10928194A IL 109281 A IL109281 A IL 109281A
- Authority
- IL
- Israel
- Prior art keywords
- stable
- xenon
- subject
- mole percent
- krypton
- Prior art date
Links
- 229910052724 xenon Inorganic materials 0.000 title claims description 111
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 title claims description 111
- 229910052743 krypton Inorganic materials 0.000 title claims description 85
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 title claims description 85
- 238000000034 method Methods 0.000 title claims description 52
- 238000002595 magnetic resonance imaging Methods 0.000 title claims description 46
- 239000000203 mixture Substances 0.000 claims description 42
- 150000002632 lipids Chemical class 0.000 claims description 40
- 230000005291 magnetic effect Effects 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 18
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 17
- 239000001301 oxygen Substances 0.000 claims description 17
- 229910052760 oxygen Inorganic materials 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 238000002347 injection Methods 0.000 claims description 12
- 239000007924 injection Substances 0.000 claims description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 11
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 9
- 238000001802 infusion Methods 0.000 claims description 8
- 230000035479 physiological effects, processes and functions Effects 0.000 claims description 8
- 239000001569 carbon dioxide Substances 0.000 claims description 7
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 7
- 239000001307 helium Substances 0.000 claims description 7
- 229910052734 helium Inorganic materials 0.000 claims description 7
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 claims description 7
- 230000009291 secondary effect Effects 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 238000011158 quantitative evaluation Methods 0.000 claims description 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000007789 gas Substances 0.000 description 66
- 210000001519 tissue Anatomy 0.000 description 35
- 239000008280 blood Substances 0.000 description 30
- 210000004369 blood Anatomy 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 20
- 210000004556 brain Anatomy 0.000 description 11
- 230000008901 benefit Effects 0.000 description 10
- 230000008499 blood brain barrier function Effects 0.000 description 9
- 210000001218 blood-brain barrier Anatomy 0.000 description 9
- 210000005013 brain tissue Anatomy 0.000 description 9
- 238000003384 imaging method Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 102000018146 globin Human genes 0.000 description 7
- 108060003196 globin Proteins 0.000 description 7
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000002616 MRI contrast agent Substances 0.000 description 5
- 230000003727 cerebral blood flow Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 229910052754 neon Inorganic materials 0.000 description 5
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 5
- 230000003444 anaesthetic effect Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000005415 magnetization Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 210000004789 organ system Anatomy 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229910052688 Gadolinium Inorganic materials 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 210000001601 blood-air barrier Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- FHNFHKCVQCLJFQ-IGMARMGPSA-N xenon-131 Chemical compound [131Xe] FHNFHKCVQCLJFQ-IGMARMGPSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004781 brain capillary Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000007404 cerebral physiology Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007435 diagnostic evaluation Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002075 inversion recovery Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000001455 metallic ions Chemical class 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000009290 primary effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- KEAYESYHFKHZAL-IGMARMGPSA-N sodium-23 atom Chemical compound [23Na] KEAYESYHFKHZAL-IGMARMGPSA-N 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
- G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
- G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- High Energy & Nuclear Physics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Signal Processing (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Optics & Photonics (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/047,019 US5357959A (en) | 1993-04-16 | 1993-04-16 | Altered dipole moment magnetic resonance imaging method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL109281A0 IL109281A0 (en) | 1994-07-31 |
| IL109281A true IL109281A (en) | 1998-12-06 |
Family
ID=21946624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL10928194A IL109281A (en) | 1993-04-16 | 1994-04-11 | Method of using xenon and / or krypton as contrast agents in magnetic resonance imaging |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5357959A (ko) |
| EP (1) | EP0620447B1 (ko) |
| JP (1) | JP2807964B2 (ko) |
| KR (1) | KR0177532B1 (ko) |
| CN (1) | CN1093893A (ko) |
| BR (1) | BR9401499A (ko) |
| CA (1) | CA2121377C (ko) |
| DE (1) | DE69427931T2 (ko) |
| ES (1) | ES2158873T3 (ko) |
| IL (1) | IL109281A (ko) |
| TW (1) | TW281629B (ko) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5494036A (en) * | 1993-11-26 | 1996-02-27 | Medrad, Inc. | Patient infusion system for use with MRI |
| US5617861A (en) * | 1994-02-16 | 1997-04-08 | Huntington Medical Research Institutes | Magnetic resonance spectral analysis of the brain for diagnosis of clinical conditions |
| US5545396A (en) * | 1994-04-08 | 1996-08-13 | The Research Foundation Of State University Of New York | Magnetic resonance imaging using hyperpolarized noble gases |
| US6123919A (en) * | 1994-04-08 | 2000-09-26 | The Trustees Of Princeton University | Magnetic resonance imaging using hyperpolarized noble gases |
| US5617860A (en) * | 1995-06-07 | 1997-04-08 | Smithsonian Astrophysical Observatory | Method and system for producing polarized 129 Xe gas |
| USH1968H1 (en) * | 1995-06-07 | 2001-06-05 | General Electric Company | Hyperpolarized MR imaging using pulse sequence with progressively increasing flip angle |
| US5611340A (en) * | 1995-10-02 | 1997-03-18 | General Electric Company | Apparatus and methods for magnetic resonance (MR) angiography using hydrogen polarized at low temperatures |
| US5617859A (en) * | 1995-10-02 | 1997-04-08 | General Electric Company | Apparatus and methods for magnetic resonance (MR) imaging of cavities using fluids polarized at low temperatures |
| WO1997037239A1 (en) | 1996-03-29 | 1997-10-09 | Lawrence Berkeley National Laboratory | Enhancement of nmr and mri in the presence of hyperpolarized noble gases |
| US8765099B2 (en) * | 1996-04-08 | 2014-07-01 | Koninklijke Philips N.V. | Magnetic resonance imaging hyperpolarization of liquids or solids by light with orbital angular momentum |
| IL119623A0 (en) * | 1996-11-15 | 1997-02-18 | Inta Medics Ltd | Non-invasive real time diagnosis of migraine |
| US6085743A (en) * | 1997-05-30 | 2000-07-11 | The Regent Of The University Of Michigan | Polarized gas delivery system/method |
| US6198957B1 (en) | 1997-12-19 | 2001-03-06 | Varian, Inc. | Radiotherapy machine including magnetic resonance imaging system |
| US6176838B1 (en) * | 1998-01-29 | 2001-01-23 | Anzai Medical Kabushiki Kaisha | Method and apparatus for measuring hepatic blood flow amount |
| JP2002510537A (ja) * | 1998-04-08 | 2002-04-09 | ザ ジェネラル ホスピタル コーポレーション | 薬理検査用ｍｒｉ（ｐｈｍｒｉ） |
| JP2002518651A (ja) * | 1998-06-17 | 2002-06-25 | メディ‐フィジクス，インコーポレイテッド | 過分極ガス輸送装置及びその輸送方法 |
| US6125654A (en) * | 1998-10-16 | 2000-10-03 | Syracuse University | Bulk production and usage of hyperpolarized 129 Xenon |
| US6284222B1 (en) | 1998-11-03 | 2001-09-04 | Medi--Physics, Inc. | Hyperpolarized helium-3 microbubble gas entrapment methods |
| GB9828853D0 (en) * | 1998-12-30 | 1999-02-17 | Nycomed Amersham Plc | Nmr spectroscopy method |
| US6295465B1 (en) * | 1999-02-17 | 2001-09-25 | Siemens Medical Systems, Inc. | Myocardial perfusion studies using magnetic resonance imaging |
| WO2000050914A1 (en) | 1999-02-23 | 2000-08-31 | Medi-Physics, Inc. | Portable system for monitoring the polarization level of a hyperpolarized gas during transport |
| US6708053B1 (en) | 1999-03-04 | 2004-03-16 | Science And Technology Corp. @ Unm | Biochemical markers of brain function |
| DE19910986C2 (de) * | 1999-03-11 | 2001-06-07 | Aga Ab | Verwendung von Xenon bei der Behandlung von Neurointoxikationen |
| US6385479B1 (en) | 1999-03-31 | 2002-05-07 | Science & Technology Corporation @ Unm | Method for determining activity in the central nervous system |
| US6295834B1 (en) | 1999-06-30 | 2001-10-02 | Medi-Physics, Inc. | NMR polarization monitoring coils, hyperpolarizers with same, and methods for determining the polarization level of accumulated hyperpolarized noble gases during production |
| US6648130B1 (en) * | 1999-08-11 | 2003-11-18 | Medi-Physics, Inc. | Hyperpolarized gas transport and storage devices and associated transport and storage methods using permanent magnets |
| KR100577410B1 (ko) * | 1999-11-30 | 2006-05-08 | 엘지.필립스 엘시디 주식회사 | 엑스레이 영상 감지소자 및 그 제조방법 |
| US6704592B1 (en) * | 2000-06-02 | 2004-03-09 | Medrad, Inc. | Communication systems for use with magnetic resonance imaging systems |
| US6652833B2 (en) | 2000-07-13 | 2003-11-25 | The Regents Of The University Of California | Functionalized active-nucleus complex sensor |
| US20030165431A1 (en) * | 2000-07-13 | 2003-09-04 | The Regents Of The University Of California | Method for detecting macromolecular conformational change and binding information |
| US7061237B2 (en) * | 2000-07-13 | 2006-06-13 | The Regents Of The University Of California | Remote NMR/MRI detection of laser polarized gases |
| US20020102211A1 (en) * | 2000-12-07 | 2002-08-01 | Renshaw Perry F. | Use of magnetic resonance imaging in diagnosis of membrane fluidity-related disorders |
| US7417428B2 (en) * | 2003-04-24 | 2008-08-26 | Koninklijke Philips Electronics N.V. | Fibre tracking magnetic resonance imaging |
| DE102005026604A1 (de) * | 2005-06-09 | 2006-12-14 | Membrana Gmbh | Verfahren zum Lösen von Gasen mit kurzlebigen physikalischen Eigenschaften in einer Flüssigkeit |
| US20090264733A1 (en) * | 2008-04-17 | 2009-10-22 | Regents Of The University Of Minnesota | Mri contrast using high transverse relaxation rate contrast agent |
| US9841480B2 (en) | 2009-04-02 | 2017-12-12 | Regents Of The University Of Minnesota | Localization of magnetic particles by means of swift-MRI |
| US8636980B2 (en) * | 2009-06-19 | 2014-01-28 | Koninklijke Philips N.V. | MRI thermometry combined with hyperpolarisation device using photons with orbital angular momentum |
| EP3258850B1 (en) * | 2015-02-20 | 2020-06-24 | Bayer HealthCare LLC | Contrast imaging agent with dissolved gas-evolving fluid |
| TWI611795B (zh) * | 2016-07-18 | 2018-01-21 | 許百靈 | 多針孔單光子ｓｐｅｃｔ心肌血流絕對定量方法與用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4586511A (en) * | 1983-03-04 | 1986-05-06 | Children's Hospital Medical Center | Methods and compositions for detecting and imaging a gas in an animal by nuclear magnetic resonance |
| JPS6347692A (ja) * | 1986-08-14 | 1988-02-29 | Toushina Seiki:Kk | 気圧変化警報装置 |
| US4893627A (en) * | 1988-05-26 | 1990-01-16 | The United States Of America As Represented By The United States Department Of Energy | Method for nuclear magnetic resonance imaging using deuterum as a contrast agent |
| US5186924A (en) * | 1991-01-16 | 1993-02-16 | Praxair Technology Inc. | Magnetic resonance human medical and veterinary imaging method |
| US5046498A (en) * | 1991-01-16 | 1991-09-10 | Union Carbide Industrial Gases Technology Corporation | Magnetic resonance human medical and veterinary imaging method |
| US5099834A (en) * | 1991-07-16 | 1992-03-31 | Union Carbide Industrial Gases Technology Corporation | Method for anesthesia |
-
1993
- 1993-04-16 US US08/047,019 patent/US5357959A/en not_active Expired - Fee Related
-
1994
- 1994-04-11 IL IL10928194A patent/IL109281A/en not_active IP Right Cessation
- 1994-04-15 EP EP94105891A patent/EP0620447B1/en not_active Expired - Lifetime
- 1994-04-15 CN CN94104432A patent/CN1093893A/zh active Pending
- 1994-04-15 BR BR9401499A patent/BR9401499A/pt not_active Application Discontinuation
- 1994-04-15 JP JP6101481A patent/JP2807964B2/ja not_active Expired - Lifetime
- 1994-04-15 KR KR1019940007927A patent/KR0177532B1/ko not_active IP Right Cessation
- 1994-04-15 ES ES94105891T patent/ES2158873T3/es not_active Expired - Lifetime
- 1994-04-15 CA CA002121377A patent/CA2121377C/en not_active Expired - Fee Related
- 1994-04-15 DE DE69427931T patent/DE69427931T2/de not_active Expired - Fee Related
- 1994-04-15 TW TW083103367A patent/TW281629B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| DE69427931D1 (de) | 2001-09-20 |
| CA2121377C (en) | 2000-10-31 |
| ES2158873T3 (es) | 2001-09-16 |
| EP0620447A3 (en) | 1995-06-14 |
| KR0177532B1 (ko) | 1999-04-01 |
| DE69427931T2 (de) | 2002-04-04 |
| JP2807964B2 (ja) | 1998-10-08 |
| EP0620447A2 (en) | 1994-10-19 |
| EP0620447B1 (en) | 2001-08-16 |
| KR940023441A (ko) | 1994-11-17 |
| CN1093893A (zh) | 1994-10-26 |
| IL109281A0 (en) | 1994-07-31 |
| BR9401499A (pt) | 1994-12-13 |
| US5357959A (en) | 1994-10-25 |
| CA2121377A1 (en) | 1994-10-17 |
| JPH06319721A (ja) | 1994-11-22 |
| TW281629B (ko) | 1996-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5357959A (en) | Altered dipole moment magnetic resonance imaging method | |
| US10967076B2 (en) | Use of non-labeled sugars and detection by MRI for assessing tissue perfusion and metabolism | |
| US7769423B2 (en) | MRI imageable liposomes for the evaluation of treatment efficacy, thermal distribution, and demonstration of dose painting | |
| Nikolaou et al. | Quantification of pulmonary blood flow and volume in healthy volunteers by dynamic contrast-enhanced magnetic resonance imaging using a parallel imaging technique | |
| US5046498A (en) | Magnetic resonance human medical and veterinary imaging method | |
| Driehuys et al. | Pulmonary perfusion and xenon gas exchange in rats: MR imaging with intravenous injection of hyperpolarized 129Xe | |
| US5186924A (en) | Magnetic resonance human medical and veterinary imaging method | |
| JP2005503221A (ja) | 偏極１２９ｘｅを用いる慢性心不全のような心肺障害を評価するための方法を含む、生理学的状態、および／または器官もしくは系の機能のインビボ評価のための方法 | |
| US7805176B2 (en) | Exchange-weighted xenon-129 nuclear magnetic resonance system and related method | |
| Altes et al. | Pulmonary embolism: comprehensive evaluation with MR ventilation and perfusion scanning with hyperpolarized helium-3, arterial spin tagging, and contrast-enhanced MRA | |
| ES2751724T3 (es) | Detección in vivo de una molécula jaula enlazante del xenón | |
| Brix et al. | Intra-and extracellular fluorouracil uptake: assessment with contrast-enhanced metabolic F-19 MR imaging. | |
| Yu et al. | Correlation of the R1 and R2 values of gadolinium-based MRI contrast media with the ΔHounsfield unit of CT contrast media of identical concentration | |
| RU2330609C1 (ru) | Способ магнитно-резонансной томографической диагностики ишемических нарушений коронарного кровообращения | |
| Dillenseger et al. | Is Subcutaneous Route an Alternative to Intravenous Route for Mouse Contrast‐Enhanced Magnetic Resonance Imaging at 1.5 T? | |
| Pirogov et al. | Advances in magnetic resonance tomography | |
| Bluemke | Magnetic resonance imaging of oxygen nano-carriers for the treatment of hypoxic tumours | |
| Naumova et al. | Yury Galina Dmitry AEV Pirogov1, Pavlovskaya2, 3, Volkov1, Nikolay Natalia Elnur V. Semenova4, 5, 6, Anisimov1, Sadykhov1, Olga Anna Mikhail S. Pavlova1 | |
| Dillenseger et al. | Research Article Is Subcutaneous Route an Alternative to Intravenous Route for Mouse Contrast-Enhanced Magnetic Resonance Imaging at 1.5 T? | |
| JP2005312821A (ja) | 高偏極核種を用いて組織内の血流量及び縦緩和時間を計測する方法 | |
| Eberle et al. | Oxygen-Sensitive Imaging, Gas Exchange | |
| Jivan | The quantitative assessment of human myocardial perfusion in vivo using dynamic magnetic resonance imaging | |
| Muradyan | Structural and functional pulmonary imaging using hyperpolzarized xenon-129 | |
| Walvick | Magnetic Resonance Imaging of Neural and Pulmonary Vascular Function: A Dissertation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |